Kayne Anderson Rudnick Investment Management LLC reduced its position in shares of Amgen Inc. (NASDAQ:AMGN) by 1.3% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 132,497 shares of the medical research company’s stock after selling 1,688 shares during the period. Kayne Anderson Rudnick Investment Management LLC’s holdings in Amgen were worth $20,159,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. Capital Advisors Inc. OK boosted its stake in shares of Amgen by 3.5% in the second quarter. Capital Advisors Inc. OK now owns 72,319 shares of the medical research company’s stock valued at $11,003,000 after buying an additional 2,442 shares in the last quarter. Glassman Wealth Services boosted its stake in shares of Amgen by 480.0% in the second quarter. Glassman Wealth Services now owns 725 shares of the medical research company’s stock valued at $110,000 after buying an additional 600 shares in the last quarter. Oak Associates Ltd. OH boosted its stake in shares of Amgen by 0.9% in the second quarter. Oak Associates Ltd. OH now owns 212,615 shares of the medical research company’s stock valued at $32,349,000 after buying an additional 1,905 shares in the last quarter. Eaton Vance Management boosted its stake in shares of Amgen by 24.8% in the second quarter. Eaton Vance Management now owns 1,875,168 shares of the medical research company’s stock valued at $285,307,000 after buying an additional 372,803 shares in the last quarter. Finally, OLD National Bancorp IN boosted its stake in shares of Amgen by 91.4% in the second quarter. OLD National Bancorp IN now owns 3,820 shares of the medical research company’s stock valued at $581,000 after buying an additional 1,824 shares in the last quarter. 79.15% of the stock is currently owned by institutional investors.
Shares of Amgen Inc. (NASDAQ:AMGN) traded down 0.21% during midday trading on Friday, hitting $175.25. The company had a trading volume of 1,040,863 shares. The stock’s 50-day moving average price is $172.03 and its 200-day moving average price is $159.88. The company has a market cap of $131.15 billion, a price-to-earnings ratio of 17.93 and a beta of 0.87. Amgen Inc. has a 12 month low of $130.09 and a 12 month high of $176.85.
Amgen (NASDAQ:AMGN) last announced its earnings results on Wednesday, July 27th. The medical research company reported $2.84 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.74 by $0.10. Amgen had a return on equity of 29.30% and a net margin of 33.07%. The company had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.58 billion. During the same period in the prior year, the company posted $2.57 EPS. Amgen’s quarterly revenue was up 5.9% on a year-over-year basis. On average, equities research analysts forecast that Amgen Inc. will post $11.36 EPS for the current year.
The firm also recently announced a quarterly dividend, which was paid on Thursday, September 8th. Shareholders of record on Wednesday, August 17th were given a $1.00 dividend. This represents a $4.00 dividend on an annualized basis and a dividend yield of 2.28%. The ex-dividend date of this dividend was Monday, August 15th. Amgen’s payout ratio is 40.90%.
Several analysts have recently issued reports on the stock. BMO Capital Markets reissued an “outperform” rating and set a $190.00 price target on shares of Amgen in a research report on Thursday. Jefferies Group reissued a “buy” rating and set a $198.00 price target on shares of Amgen in a research report on Tuesday, August 23rd. Vetr raised shares of Amgen from a “sell” rating to a “hold” rating and set a $171.34 price target on the stock in a research report on Wednesday, August 3rd. Leerink Swann reissued a “hold” rating on shares of Amgen in a research report on Saturday, September 17th. Finally, Credit Suisse Group AG set a $206.00 price target on shares of Amgen and gave the stock a “buy” rating in a research report on Saturday, September 17th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and twelve have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $184.56.
In other Amgen news, VP Annette Louise Such sold 3,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 2nd. The stock was sold at an average price of $174.59, for a total value of $523,770.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.20% of the stock is owned by company insiders.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.